Interstitial Cystitis Market Report 2026

The interstitial cystitis market size has grown strongly in recent years. It will grow from $1.96 billion in 2025 to $2.12 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to underdiagnosis of interstitial cystitis, increasing prevalence of chronic pelvic pain disorders, wider use of oral antidepressants and antihistamines, growth of urology specialty clinics, rising healthcare consultations for bladder pain.

The interstitial cystitis market size is expected to see strong growth in the next few years. It will grow to $3.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing research into ic pathophysiology, growing demand for personalized treatment regimens, rising adoption of nerve stimulation therapies, expanding homecare treatment options, improved clinical guidelines and diagnostic criteria. Major trends in the forecast period include increasing focus on early and accurate diagnosis, rising use of multimodal pain management approaches, growing adoption of minimally invasive therapies, expansion of patient-centered and long-term care models, improved awareness and diagnosis of chronic bladder disorders.

The increasing incidence of urinary tract infections is anticipated to drive the growth of the interstitial cystitis market. Urinary tract infections are bacterial infections that can affect any part of the urinary system and occur when bacteria enter through the urethra. UTIs can directly or indirectly cause bacterial cystitis, and if left untreated, they may result in chronic bladder inflammation, which is a key underlying factor in interstitial cystitis. Managing urinary tract infections associated with interstitial cystitis helps reduce pain and enhances the quality of life for affected patients. For example, in January 2024, a research article published by the National Kidney Foundation Inc., a U.S.-based organization focused on awareness, prevention, and treatment of kidney disease, reported that approximately 50%-60% of women experience a UTI at least once in their lifetime. Consequently, the growing prevalence of urinary tract infections is expected to fuel the interstitial cystitis market.

Leading companies in the interstitial cystitis treatment market are concentrating on initiating new phases of clinical trials to develop novel therapies and boost market revenues. Advanced treatment approaches aim to improve patient care and outcomes for this chronic and often complex bladder disorder. For example, in May 2023, Vaneltix Pharma, Inc. collaborated with Prevail Infoworks, Inc. to initiate a Phase 2 clinical study. The study evaluates the safety and effectiveness of VNX001 compared with its individual components (lidocaine and heparin) or a placebo in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). Currently recruiting participants, this collaboration integrates pharmaceutical development with analytics expertise to accelerate potential IC/BPS therapies, reflecting a strong focus on innovation in healthcare.

In June 2023, Ironwood Pharmaceuticals, a U.S.-based pharmaceutical company, completed a merger with VectivBio Holding AG for an undisclosed value. Through this transaction, Ironwood aims to enhance its gastrointestinal product pipeline, with a particular emphasis on therapies for rare and underserved diseases. This move supports Ironwood’s strategy to broaden its presence in the gastrointestinal space while utilizing VectivBio’s capabilities in rare disease drug development. VectivBio Holding AG is a Switzerland-based, clinical-stage biopharmaceutical company specializing in treatments for rare gastrointestinal disorders.

Major companies operating in the interstitial cystitis market are Astellas Pharma Inc, Perrigo Company plc, Aurobindo Pharma Ltd, Purdue Pharma LP, Apotex Inc, Endo International plc, Amneal Pharmaceuticals Inc, Alvogen Inc., Kyorin Pharmaceutical Co. Ltd, Seikagaku Corp, Strides Pharma Science Limited, AlgoTherapeutix SAS.

North America was the largest region in the interstitial cystitis market in 2025. The regions covered in the interstitial cystitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interstitial cystitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the interstitial cystitis market by increasing costs of imported pharmaceuticals, medical devices for nerve stimulation, and specialized bladder instillation materials. These effects are most evident in advanced therapy segments such as botulinum toxin injections and nerve stimulation, particularly across asia-pacific and europe where reliance on imported medical supplies is high. Higher tariffs have raised treatment costs for hospitals and clinics. However, tariffs are also encouraging domestic drug manufacturing, localized device production, and supply chain diversification, supporting long-term market resilience.

The interstitial cystitis market research report is one of a series of new reports that provides interstitial cystitis market statistics, including interstitial cystitis industry global market size, regional shares, competitors with a interstitial cystitis market share, detailed interstitial cystitis market segments, market trends and opportunities, and any further data you may need to thrive in the interstitial cystitis industry. This interstitial cystitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interstitial cystitis (IC) is a long-term disorder that leads to bladder pain and pressure, which may range from mild to severe and can be persistent or intermittent. It is defined by pain, pressure, or discomfort related to the urinary bladder that continues for more than six months. Treatments such as tricyclic antidepressants, antihistamines, and bladder instillations are used to alleviate pain and help reduce inflammation.

The primary treatment approaches for interstitial cystitis include medications, bladder instillation, botulinum toxin A therapy, nerve stimulation, and surgical interventions. Interstitial cystitis medications encompass a range of drugs and therapeutic options used to control the symptoms of this chronic inflammatory bladder condition. Patient groups include both pediatric and adult patients, with treatment options consisting of over-the-counter (OTC) drugs and prescription medications. The main end users of these treatments are hospitals, clinics, and home care settings.

The interstitial cystitis market include revenues earned through entities by providing services such as physical therapy, oral medications, nerve stimulation and bladder distention. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.